DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,074 filers reported holding DANAHER CORPORATION in Q4 2022. The put-call ratio across all filers is 1.10 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,446,942 | +45.5% | 5,832 | +40.7% | 0.18% | +58.0% |
| Q2 2023 | $994,666 | +37.7% | 4,144 | +44.5% | 0.11% | +36.6% |
| Q1 2023 | $722,587 | -6.9% | 2,867 | -1.9% | 0.08% | -5.7% |
| Q4 2022 | $776,163 | -99.9% | 2,924 | -10.4% | 0.09% | -10.3% |
| Q3 2022 | $842,838,000 | -1.9% | 3,263 | -3.7% | 0.10% | +5.4% |
| Q2 2022 | $858,844,000 | +77483.0% | 3,388 | -10.2% | 0.09% | -7.1% |
| Q1 2022 | $1,107,000 | -34.7% | 3,774 | -26.7% | 0.10% | -20.2% |
| Q4 2021 | $1,695,000 | +11.4% | 5,152 | +3.1% | 0.12% | +6.9% |
| Q3 2021 | $1,522,000 | +12.6% | 4,998 | -0.8% | 0.12% | +14.9% |
| Q2 2021 | $1,352,000 | +3.9% | 5,039 | -12.9% | 0.10% | 0.0% |
| Q1 2021 | $1,301,000 | +4.8% | 5,782 | +3.5% | 0.10% | -25.7% |
| Q4 2020 | $1,241,000 | -8.1% | 5,587 | -10.9% | 0.14% | -7.5% |
| Q3 2020 | $1,350,000 | +4.3% | 6,268 | -14.3% | 0.15% | +4.3% |
| Q2 2020 | $1,294,000 | +4.9% | 7,315 | -3.9% | 0.14% | +29.4% |
| Q1 2020 | $1,233,000 | +7.7% | 7,614 | +2.1% | 0.11% | +7.9% |
| Q4 2019 | $1,145,000 | -23.5% | 7,458 | -28.1% | 0.10% | -22.3% |
| Q3 2019 | $1,497,000 | -7.2% | 10,368 | -8.2% | 0.13% | -3.7% |
| Q2 2019 | $1,614,000 | +0.7% | 11,296 | -6.9% | 0.14% | +4.7% |
| Q1 2019 | $1,602,000 | +20.9% | 12,133 | -5.6% | 0.13% | +25.2% |
| Q4 2018 | $1,325,000 | -25.1% | 12,850 | -24.8% | 0.10% | -7.2% |
| Q3 2018 | $1,769,000 | +55.6% | 17,085 | +48.3% | 0.11% | +63.2% |
| Q2 2018 | $1,137,000 | +349.4% | 11,519 | +346.3% | 0.07% | +423.1% |
| Q1 2018 | $253,000 | +13.5% | 2,581 | +7.3% | 0.01% | +18.2% |
| Q4 2017 | $223,000 | -21.2% | 2,406 | -27.1% | 0.01% | -31.2% |
| Q3 2017 | $283,000 | +7.6% | 3,300 | +5.8% | 0.02% | +6.7% |
| Q2 2017 | $263,000 | -3.7% | 3,118 | -2.1% | 0.02% | -6.2% |
| Q1 2017 | $273,000 | -48.9% | 3,186 | -53.6% | 0.02% | -52.9% |
| Q4 2016 | $534,000 | +9.4% | 6,864 | +10.3% | 0.03% | +9.7% |
| Q3 2016 | $488,000 | +96.8% | 6,222 | +153.0% | 0.03% | +82.4% |
| Q2 2016 | $248,000 | -2.0% | 2,459 | -7.8% | 0.02% | -5.6% |
| Q1 2016 | $253,000 | -1.2% | 2,667 | -3.1% | 0.02% | -5.3% |
| Q4 2015 | $256,000 | -48.4% | 2,752 | -75.2% | 0.02% | -62.7% |
| Q3 2015 | $496,000 | – | 11,090 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |